The antitumor response of the B16-LX/IL(15 + 7) vaccine was tumor-specific, as it did not inhibit the growth of antigenically distinct EL-4 lymphomas [31] (Fig. 3; Table 1). The gene discussed is IL15; the disease is neoplasm.